DCVC Bio

Amazing news from Radionetics Oncology!! DCVC Bio is super proud. https://lnkd.in/gnxkk4eE

The world needs this, now. Find out how CH4Global is on track to deliver gigaton-scale greenhouse gas emissions reductions by 2030 using a humble red seaweed called Asparagopsis. 👇 https://lnkd.in/gNxW_3NA

Big news from Chroma Medicine!

Cadillac Advanced Color, Materials and Finishes designers collaborated with MycoWorks to develop a new material, created using our Fine Mycelium™ technology, that incorporates the renewable root structure of mushrooms and other bio-based ingredients.   Cadillac’s exploration using Fine Mycelium™ will be a first for the automotive industry, underscoring the brand’s dedication to forward-thinking design, technological advancements, and offering innovative materials and resources for automotive designers. “The Fine Mycelium™ material is a pure example and exploration of revolutionary resources and collaborations that contribute to an innovative design future. Working with the material and learning about its unique properties, will help to create beautiful texture options impacting future automotive interior applications.” – Hannah Dunbar, industrial designer, Cadillac We’re excited for the innovations our collaboration will bring to the automotive industry! Learn more: https://lnkd.in/gJpgFd2c

At Creyon, we're transforming nucleic acid drug discovery through our pioneering work on Oligonucleotide-Based Medicines (OBMs). While OBMs like ASOs and siRNAs can precisely target genetic diseases, addressing off-target effects is crucial and traditional genome-wide methods have been limited in scope and accuracy. Our latest research introduces DoReSeq, a technique to quantify off-target transcriptome-wide effects in OBMs with high accuracy and confidence scores. DoReSeq enables us to engineer more precise and effective OBM therapeutics and helps us unlock the full potential of these medicines. This is a significant step in our efforts to transform nucleic acid drug discovery to drug engineering, moving beyond failure prone trial-and-error processes for optimizing safety and efficacy. Read more in our latest research, featured in a preprint publication in bioRxiv & medRxiv: https://lnkd.in/e9mb3_Us

Creyon Bio Lux Capital DCVC Bio TNPO2 Foundation Another article that features our hard and exciting work. Gratitude to the teams involved on all sides of the effort! I am proud of us.

The #banana is on limited time. That’s why we’re on a mission to prevent its #extinction. Take a listen to this podcast from North Carolina Public Radio-WUNC as they dive into the history of the world’s most popular fruit, and how we’ve cracked the code to saving it. #AgTech #Innovation #FutureofFood #Agriculture

Creyon Bio is changing how #oligo drugs are made. As a piece of their transformative approach, they present a method that can quantify off-targets transcriptome-wide with high accuracy, including confidence estimates, that will greatly increase the ability to engineer precise Oligo drugs without off-target effects.

#AI enabled #drug development has altered risk and timelines drastically before our eyes. More importantly, patients and families are being better cared for. Kudos to the #TNPO2 foundation and Creyon Bio

News alert 📰 Exciting developments for the #Alchemab team as a peer-reviewed article has been published in Nature Immunology, Nature Portfolio, highlighting Alchemab's capabilities and potential to develop new #cancer therapies. In cancer, Alchemab focuses on identifying #antibodies from patients with certain solid tumors who are long-term survivors of the disease.   Find out more about Alchemab's preliminary work and identification of antibodies associated with checkpoint inhibition, angiogenesis, and cytokine modulation in cancer survivors in the press release linked in the comments.   #biotech #lifesciences #oncology Rachael Bashford-Rogers